$LUNG

Radhakrishnan Srikanth sold $3K of LUNG

Radhakrishnan Srikanth (Chief Science &Techn. Officer) sold 2,153 shares of Pulmonx Corp (LUNG) at $1.54 on 2026-06-01.

Original reporting
SEC EDGAR · Radhakrishnan Srikanth
Published Jun 3, 2026, 8:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 3, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$LUNG
Neutral
medium confidence
Mentioned
$LUNG
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LUNGNeutralLow
01

Why it matters

Insider selling disclosures can influence short-term sentiment, but without accompanying fundamental updates (earnings, trial results, guidance, deals) the trading signal is typically weak.

02

Market read

A routine insider sale disclosure; likely limited incremental impact on valuation absent other catalysts.

03

What to watch

The sale is under an open-market transaction and the filing notes no pre-arranged 10b5-1 plan, but the disclosed value is small and not clearly tied to a broader change.

Relevance 4/10Novelty 3/10Timing: After-hours SEC Form 4 filed 2026-06-03; reflects sale executed 2026-06-01.

Background

The article is an SEC insider transaction (Form 4) disclosure for Pulmonx Corp.

Company-level read

Ticker impact

$LUNGNeutralMedium confidence
Context

Pulmonx insider Form 4 shows CSO Radhakrishnan Srikanth sold 2,153 shares in an open-market transaction on 2026-06-01.

Expected impact

Low near-term impact; any move is likely sentiment-driven and should be weighed against overall tape/volume.

Evidence & confidence

The filing is a routine insider transaction with small dollar value (~$3.3K) and no stated link to new company fundamentals.

Market effects

Minimal; single-company insider transaction without sector-wide signal.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for diversification or liquidity needs and may not reflect negative views on the business.

Key entities

  • Pulmonx Corp

    US-listed company (LUNG) whose insider transaction was disclosed via SEC Form 4.

  • Radhakrishnan Srikanth

    Chief Science & Techn. Officer who sold 2,153 shares at $1.5400/share.

Related articles

$GCTKMed

Top Biotech Gainers: GCTK On The Move, BHC, CORT Boost FY'26 Outlook, NEOG On Watch

Today's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.

$LUNGMed

Pulmonx Stock Rises On Narrowed Q2 Losses, Margin Gains

Pulmonx (LUNG) reported Q2 2026 results for the quarter ended June 30, 2026. Revenue fell 5% to $22.8M, while gross profit rose to $17.7M and gross margin increased to 78%. Net loss narrowed to $10.1M ($0.24/share). The company reaffirmed FY2026 revenue guidance of $90M-$92M and gross margin around 76%.

$LUNGMed

Pulmonx Corp (LUNG): Results of Operations and Financial Condition

Pulmonx Corp (LUNG) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 lung2q26earningsrelease072.htm EX-99.1 Document Exhibit 99.1 Pulmonx Reports Second Quarter 2026 Financial Results Redwood City, CA - July 29, 2026 – Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lu